Soros Fund Management LLC Has $13.69 Million Position in Privia Health Group, Inc. (NASDAQ:PRVA)

Soros Fund Management LLC reduced its position in Privia Health Group, Inc. (NASDAQ:PRVA - Free Report) by 6.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 700,000 shares of the company's stock after selling 50,000 shares during the period. Soros Fund Management LLC owned about 0.58% of Privia Health Group worth $13,685,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Barclays PLC lifted its holdings in shares of Privia Health Group by 240.3% in the third quarter. Barclays PLC now owns 224,018 shares of the company's stock valued at $4,079,000 after purchasing an additional 158,188 shares in the last quarter. Virtu Financial LLC purchased a new stake in Privia Health Group in the 3rd quarter worth about $263,000. Franklin Resources Inc. boosted its position in Privia Health Group by 2.2% during the 3rd quarter. Franklin Resources Inc. now owns 1,300,240 shares of the company's stock worth $23,092,000 after acquiring an additional 28,480 shares during the period. JPMorgan Chase & Co. grew its stake in Privia Health Group by 8.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 188,384 shares of the company's stock valued at $3,430,000 after acquiring an additional 14,641 shares in the last quarter. Finally, Nordea Investment Management AB boosted its holdings in shares of Privia Health Group by 33.1% during the fourth quarter. Nordea Investment Management AB now owns 349,773 shares of the company's stock worth $6,953,000 after purchasing an additional 86,910 shares during the period. Institutional investors and hedge funds own 94.48% of the company's stock.

Privia Health Group Stock Up 1.8 %

Privia Health Group stock traded up $0.42 during mid-day trading on Friday, reaching $23.32. The company had a trading volume of 369,530 shares, compared to its average volume of 771,494. The company has a 50 day moving average of $23.52 and a 200-day moving average of $22.03. Privia Health Group, Inc. has a 52 week low of $15.92 and a 52 week high of $26.04. The firm has a market cap of $2.83 billion, a price-to-earnings ratio of 233.22, a PEG ratio of 3.47 and a beta of 0.88.

Insider Activity at Privia Health Group

In other Privia Health Group news, CFO David Mountcastle sold 3,445 shares of Privia Health Group stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $23.33, for a total transaction of $80,371.85. Following the completion of the transaction, the chief financial officer now directly owns 176,231 shares of the company's stock, valued at approximately $4,111,469.23. This trade represents a 1.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Parth Mehrotra sold 15,100 shares of the business's stock in a transaction dated Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total transaction of $352,283.00. Following the completion of the transaction, the chief executive officer now owns 454,281 shares in the company, valued at approximately $10,598,375.73. This trade represents a 3.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 34,484 shares of company stock worth $799,163. Company insiders own 10.70% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on PRVA shares. Piper Sandler lifted their target price on shares of Privia Health Group from $25.00 to $40.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. Stephens restated an "overweight" rating and set a $26.00 price target on shares of Privia Health Group in a research note on Thursday, January 2nd. Robert W. Baird raised their target price on Privia Health Group from $24.00 to $26.00 and gave the company an "outperform" rating in a report on Tuesday, April 15th. Needham & Company LLC reissued a "buy" rating and set a $30.00 price objective on shares of Privia Health Group in a report on Thursday, April 10th. Finally, Truist Financial boosted their target price on Privia Health Group from $27.00 to $28.00 and gave the stock a "buy" rating in a report on Thursday, April 10th. One equities research analyst has rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $27.38.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.